Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Axsome Therapeutics, Inc. ($AXSM) is set to present the topline results of the SYMPHONY Trial during a conference call at 8 am ET. Despite positive data, concerns arise about the stock's valuation and financing decisions, impacting shareholder returns. Questions linger regarding the confidence in q6m dosing for the phase 3 design of the company's mAB. The absence of a Q6M arm in the phase 3 trial is also criticized.
$ATXS data is unquestionably great but poor price action is their fault. Why did they engage in such desperate financing over the last year *when they could see open label data*? Financing at $6.50 + warrants + cash runway a year PAST Ph3 data?! Also why no Q6M arm in Ph3? Dorks
$ATAI seems to of made support at the 200 DMA With Comp 360 phase 3 data release scheduled to be released any week, and a general bump to the psychedelics sector upon any marijuana rescheduling I like the risk / reward here
$ATAI seems to of made support at the 200 DMA With Comp 360 phase 3 data release scheduled to be released any week, and a general bukb to the psychedelics sector upon any marijuana rescheduling I like the risk / reward here